An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice

Virology

Volumn 483, Issue , 2015, Pages 117-125

  Boyoglu Barnum, Seyhan ^a   Todd, Sean O ^a   Chirkova, Tatiana ^a   Barnum, Thomas R ^c   Gaston, Kelsey A ^a   Haynes, Lia M ^b   Tripp, Ralph A ^c   Moore, Martin L ^a   Anderson, Larry J ^a  

^a EMORY UNIVERSITY   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

Author keywords

Anti viral; RSV; RSV F protein; RSV G protein

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 131-2G; MONOCLONAL ANTIBODY 143-6C; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN 5AC; PALIVIZUMAB; UNCLASSIFIED DRUG; ATTACHMENT PROTEIN G; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG MECHANISM; DYSPNEA; FEMALE; LEUKOCYTE COUNT; LUNG LAVAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SPUTUM LEVEL; TISSUE LEVEL; VIRUS DETECTION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOTHERAPY; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

HUMAN RESPIRATORY SYNCYTIAL VIRUS; MUS; PARAMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOTHERAPY; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS; VIRAL FUSION PROTEINS;

EID: 84928964182     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.02.035     Document Type: Article

References (49)

1. Anon Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998, 102:531-537.
2. Anderson L.J., Bingham P., Hierholzer J.C. Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies. J. Virol. 1988, 62:4232-4238.
3. Anderson L.J., Hierholzer J.C., Bingham P.G., Stone Y.O. Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay. J. Clin. Microbiol. 1985, 22:1050-1052.
4. Anderson L.J., Hierholzer J.C., Stone Y.O., Tsou C., Fernie B.F. Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay. J. Clin. Microbiol. 1986, 23:475-480.
5. Andersson C., Liljestrom P., Stahl S., Power U.F. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. FEMS Immunol. Med. Microbiol. 2000, 29:247-253.
6. Arnold R., Konig B., Werchau H., Konig W. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 2004, 330:384-397.
7. Beeler J.A., van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J. Virol. 1989, 63:2941-2950.
8. Boyoglu-Barnum S., Chirkova T., Todd S.O., Barnum T.R., Gaston K.A., Jorquera P., Haynes L.M., Tripp R.A., Moore M.L., Anderson L.J. Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice. J. Virol. 2014, 88:10569-10583.
9. Boyoglu-Barnum S., Gaston K.A., Todd S.O., Boyoglu C., Chirkova T., Barnum T.R., Jorquera P., Haynes L.M., Tripp R.A., Moore M.L., Anderson L.J. A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J. Virol. 2013, 87:10955-10967.
10. Bukreyev A., Yang L., Fricke J., Cheng L., Ward J.M., Murphy B.R., Collins P.L. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. J. Virol. 2008, 82:12191-12204.
11. Collarini E.J., Lee F.E., Foord O., Park M., Sperinde G., Wu H., Harriman W.D., Carroll S.F., Ellsworth S.L., Anderson L.J., Tripp R.A., Walsh E.E., Keyt B.A., Kauvar L.M. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J. Immunol. 2009, 183:6338-6345.
12. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 2011, 162:80-99.
13. Connors M., Collins P.L., Firestone C.Y., Murphy B.R. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 1991, 65:1634-1637.
14. DeVincenzo J.P., Whitley R.J., Mackman R.L., Scaglioni-Weinlich C., Harrison L., Farrell E., McBride S., Lambkin-Williams R., Jordan R., Xin Y., Ramanathan S., O'Riordan T., Lewis S.A., Li X., Toback S.L., Lin S.L., Chien J.W. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N. Engl. J. Med. 2014, 371:711-722.
15. Geevarghese B., Simoes E.A. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir. Ther. 2012, 17:201-211.
16. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol. Rev. 2011, 239:149-166.
17. Groothuis J.R., Simoes E.A., Levin M.J., Hall C.B., Long C.E., Rodriguez W.J., Arrobio J., Meissner H.C., Fulton D.R., Welliver R.C., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N. Engl. J. Med. 1993, 329:1524-1530.
18. Han J., Takeda K., Wang M., Zeng W., Jia Y., Shiraishi Y., Okamoto M., Dakhama A., Gelfand E.W. Effects of anti-G and anti-F antibodies on airway function after respiratory syncytial virus infection. Am. J. Respir. Cell Mol. Biol. 2014, 51:143-154.
19. Harcourt J., Alvarez R., Jones L.P., Henderson C., Anderson L.J., Tripp R.A. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 2006, 176:1600-1608.
20. Hashimoto K., Graham B.S., Ho S.B., Adler K.B., Collins R.D., Olson S.J., Zhou W., Suzutani T., Jones P.W., Goleniewska K., O'Neal J.F., Peebles R.S. Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am. J. Respir. Crit. Care Med. 2004, 170:306-312.
21. Haynes L.M., Caidi H., Radu G.U., Miao C., Harcourt J.L., Tripp R.A., Anderson L.J. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J. Infect. Dis. 2009, 200:439-447.
22. Haynes L.M., Jones L.P., Barskey A., Anderson L.J., Tripp R.A. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P. J. Virol. 2003, 77:9831-9844.
23. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997, 176:1215-1224.
24. Kauvar L.M., Harcourt J.L., Haynes L.M., Tripp R.A. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2010, 2:655-661.
25. Krilov L.R. Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev. Anti Infect. Ther. 2011, 9:27-32.
26. Lugo R.A., Nahata M.C. Pathogenesis and treatment of bronchiolitis. Clin. Pharm. 1993, 12:95-116.
27. Maher C.F., Hussell T., Blair E., Ring C.J., Openshaw P.J. Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. Microbes Infect. 2004, 6:1049-1055.
28. Miao C., Radu G.U., Caidi H., Tripp R.A., Anderson L.J., Haynes L.M. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 2009, 90:1119-1123.
29. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O'Brien K.L., Roca A., Wright P.F., Bruce N., Chandran A., Theodoratou E., Sutanto A., Sedyaningsih E.R., Ngama M., Munywoki P.K., Kartasasmita C., Simoes E.A., Rudan I., Weber M.W., Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
30. Olmsted R.A., Elango N., Prince G.A., Murphy B.R., Johnson P.R., Moss B., Chanock R.M., Collins P.L. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. USA 1986, 83:7462-7466.
31. Oshansky C.M., Krunkosky T.M., Barber J., Jones L.P., Tripp R.A. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 2009, 22:147-161.
32. Ottolini M.G., Curtis S.J., Porter D.D., Mathews A., Richardson J.Y., Hemming V.G., Prince G.A. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob. Agents Chemother. 2002, 46:2299-2302.
33. Polack F.P., Irusta P.M., Hoffman S.J., Schiatti M.P., Melendi G.A., Delgado M.F., Laham F.R., Thumar B., Hendry R.M., Melero J.A., Karron R.A., Collins P.L., Kleeberger S.R. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc. Natl. Acad. Sci. USA 2005, 102:8996-9001.
34. Quinn S.F., Erickson S., Oshman D., Hayden F. Lobar collapse with respiratory syncytial virus pneumonitis. Pediatr. Radiol. 1985, 15:229-230.
35. Radu G.U., Caidi H., Miao C., Tripp R.A., Anderson L.J., Haynes L.M. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J. Virol. 2010, 84:9632-9636.
36. Ramilo O., Lagos R., Saez-Llorens X., Suzich J., Wang C.K., Jensen K.M., Harris B.S., Losonsky G.A., Griffin M.P. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr. Infect. Dis. J. 2014, 33:703-709.
37. Ray R., Hoft D.F., Meyer K., Brown R., Lagging L.M., Belshe R.B. Immunoregulatory role of secreted glycoprotein G from respiratory syncytial virus. Virus Res. 2001, 75:147-154.
38. Shingai M., Azuma M., Ebihara T., Sasai M., Funami K., Ayata M., Ogura H., Tsutsumi H., Matsumoto M., Seya T. Soluble G protein of respiratory syncytial virus inhibits toll-like receptor 3/4-mediated IFN-beta induction. Int. Immunol. 2008, 20:1169-1180.
39. Siegel J.D., Rhinehart E., Jackson M., Chiarello L. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am. J. Infect. Control 2007, 35:S65-S164.
40. Stokes K.L., Chi M.H., Sakamoto K., Newcomb D.C., Currier M.G., Huckabee M.M., Lee S., Goleniewska K., Pretto C., Williams J.V., Hotard A., Sherrill T.P., Peebles R.S., Moore M.L. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 2011, 85:5782-5793.
41. Stott E.J., Taylor G., Ball L.A., Anderson K., Young K.K., King A.M., Wertz G.W. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J. Virol. 1987, 61:3855-3861.
42. Tayyari F., Hegele R.G. Identifying targets in the hunt for effective respiratory syncytial virus interventions. Expert Rev. Respir. Med. 2012, 6:215-222.
43. Tripp R.A. Pathogenesis of respiratory syncytial virus infection. Viral Immunol. 2004, 17:165-181.
44. Tripp R.A., Dakhama A., Jones L.P., Barskey A., Gelfand E.W., Anderson L.J. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol. 2003, 77:6580-6584.
45. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2001, 2:732-738.
46. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 1999, 73:7099-7107.
47. Tripp R.A., Moore D., Winter J., Anderson L.J. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 2000, 74:1614-1622.
48. Waghmare A., Campbell A.P., Xie H., Seo S., Kuypers J., Leisenring W., Jerome K.R., Englund J.A., Boeckh M. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin. Infect. Dis. 2013, 57:1731-1741.
49. Zamora M.R., Budev M., Rolfe M., Gottlieb J., Humar A., Devincenzo J., Vaishnaw A., Cehelsky J., Albert G., Nochur S., Gollob J.A., Glanville A.R. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 2011, 183:531-538.